Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.
January 24, 2023 08:00 ET
|
Pharmaceutics International Inc.
Hunt Valley, MD, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I...
12-month clinical results of a novel micro-interventional bio-stenting procedure published in the British Journal of Ophthalmology
January 23, 2023 08:00 ET
|
Iantrek, Inc.
WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Iantrek today announced the publication of 12-month clinical results of a novel bio-stenting procedure using the company’s microsurgical...
Wilmington Eye Ophthalmic Surgeon Implants First-Ever Glaucoma Device in the Carolinas
December 21, 2022 11:00 ET
|
Wilmington Eye
WILMINGTON, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Today, Wilmington Eye announced Dr. Robert van der Vaart, a board-certified ophthalmic surgeon and glaucoma expert, has successfully implanted the...
iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norway
December 01, 2022 03:00 ET
|
iSTAR Medical
For immediate release iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norway The only commercially available MIGS device currently targeting the supraciliary...
Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams
October 17, 2022 09:01 ET
|
Eyenovia
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more...
Eyenovia Chairman Dr. Sean Ianchulev: The Making Of An iDoctor - Immigrant, Innovator, Inventor
September 21, 2022 10:01 ET
|
Eyenovia
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Before founding Eyenovia, Dr. Sean Ianchulev had established himself as a pioneer and innovator in the field of ophthalmology. Inspired by his mother, a...
Global Glaucoma Treatment Market Report 2022: Continuous Drug Innovations Presents Opportunities
September 20, 2022 05:18 ET
|
Research and Markets
Dublin, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Glaucoma treatment Market Research and Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global glaucoma...
Rich Insights into the Glaucoma Clinical Trial Analysis Featuring 70+ Companies and Therapies | DelveInsight
September 12, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rich Insights into the Glaucoma Clinical Trial Analysis Featuring 70+ Companies and Therapies | DelveInsight The number of clinical trials in...
Eyenovia's Novel Optejet® Dispenser Puts People's Eyes First
August 30, 2022 09:01 ET
|
Eyenovia
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, brings...
Iantrek Raises $23M Series B Financing to Advance Next Generation Ophthalmic Micro-Interventional Technologies
August 30, 2022 08:00 ET
|
Iantrek, Inc.
WHITE PLAINS, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing....